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Abstract
Background
Current tuberculosis diagnostics lack sensitivity, and are expensive. Highly accurate, rapid
and cheaper diagnostic tests are required for point of care use in low resource settings with
high HIV prevalence.
Objective
To investigate the sensitivity and specificity, and cost of loop-mediated isothermal amplifica-
tion (LAMP) assay for tuberculosis diagnosis in adults with chronic cough compared to
Xpert1MTB/RIF, fluorescence smear microscopy.
Methods
Between October 2013 and March 2014, consecutive adults at a primary care clinic were
screened for cough, offered HIV testing and assessed for tuberculosis using LAMP, Xpert1
MTB/RIF and fluorescence smear microscopy. Sensitivity and specificity (with culture as
reference standard), and costs were estimated.
Results
Of 273 adults recruited, 44.3% (121/273) were HIV-positive and 19.4% (53/273) had bacter-
iogically confirmed tuberculosis. The sensitivity of LAMP compared to culture was 65.0%
(95% CI: 48.3% to 79.4%) with 100% (95% CI: 98.0% to 100%) specificity. The sensitivity of
Xpert1MTB/RIF (77.5%, 95% CI: 61.5% to 89.2%) was similar to that of LAMP, p = 0.132.
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The sensitivity of concentrated fluorescence smear microscopy with routine double reading
(87.5%, 95% CI: 73.2% to 95.8%) was higher than that of LAMP, p = 0.020. All three tests
had high specificity. The lowest cost per test of LAMP was at batch size of 14 samples (US$
9.98); this was lower than Xpert1MTB/RIF (US$ 13.38) but higher than fluorescence
smear microscopy (US$ 0.65).
Conclusion
The sensitivity of LAMP was similar to Xpert1MTB/RIF but lower than fluorescence smear
microscopy; all three tests had high specificity. These findings support the Malawi policy
that recommends a combination of fluorescence smear microscopy and Xpert1MTB/RIF
prioritised for people living with HIV, already found to be smear-negative, or being consid-
ered for retreatment of tuberculosis.
Introduction
Early diagnosis of tuberculosis with highly accurate, rapid point of care tests is a key compo-
nent of the WHO’s End Tuberculosis Strategy [1]. The Xpert1MTB/RIF is being rolled out in
low-and middle- income countries and is now a major player in tuberculosis prevention and
care [2, 3].
The loop-mediated isothermal amplification (LAMP) assay for diagnosing tuberculosis is a
new test with a number of similarities to Xpert1MTB/RIF: it is mainly intended for use with
sputum specimens, and is a nucleic acid amplification test [4]. LAMP is less fully automated
than the Xpert1MTB/RIF system, providing both potential advantages (higher peak through-
put, and lower capital costs) and disadvantages (greater operator complexity, potential for
cross-contamination and error in interpreting visual fluorescent readout) [5]. LAMP is being
considered as a potential replacement for smear microscopy in settings with low burden of
multi-drug resistant tuberculosis, with potential cost-savings compared to Xpert1MTB/RIF
in peripheral laboratories with high volume of samples, and countries not eligible for low
income country access prices [6]. A recent meta-analysis estimated a sensitivity of 80% and
specificity of 96% for LAMP on sputum specimens compared to culture, but included studies
were mostly from countries with low burden of HIV [7].
Combined HIV testing and counselling for adults with symptoms of tuberculosis identifies
people in need of ART [8]. Although an international policy recommendation for some time,
HIV testing and counselling for adults with symptoms of tuberculosis has not been fully imple-
mented within the primary health care system in sub-Saharan Africa [9–11].
The objective of this study was to investigate the sensitivity and specificity, and costing esti-
mate of LAMP for diagnosing tuberculosis in a low resource setting with high prevalence of
HIV. The study also investigates the importance of HIV testing for adults with symptoms of
tuberculosis and provides sensitivity and specificity and costing estimates of Xpert1MTB/RIF
and concentrated fluorescence smear microscopy.
Methods
Study design and setting
This diagnostic evaluation study was conducted at Ndirande Health Centre, Blantyre, Malawi.
The health centre serves a high density urban area of Blantyre city, with population prevalence
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of HIV and tuberculosis of 18.5% and 0.9%, respectively [12, 13]. Tuberculosis diagnostic ser-
vices (with fluorescence smear microscopy and Xpert1MTB/RIF for smear negative HIV posi-
tive individuals) are routinely provided at the health centre [14]. Chest radiography and
culture are only available by referral to the city’s central hospital.
Study participants
Between October 2013 and March 2014, consecutive patients attending the outpatient depart-
ment of Ndirande Health Centre were informed about the study while in the waiting area.
Trained research assistants undertook an eligibility assessment with all facility attenders who
were willing to participate in the study. Patients were eligible if they had chronic cough (2
weeks), were at least 15 years old and were residing in Blantyre city. Participants were excluded
if they could not submit sputum, or were taking tuberculosis treatment, or had reported that
they had been treated for tuberculosis in the past.
Ethics approval was obtained from the College of Medicine of Malawi Research and Ethics
Committee. Approval number P.06/13/1397. Written informed consent was obtained from all
participants. For participants under the age of 18 years, informed written or witnessed thumb-
print participant assent and parental or guardian consent were required for recruitment.
Participant interview
Research assistants interviewed all attending eligible individuals to record socio-demographic
information and prior access to HIV care services.
All participants were asked to submit two spot sputum samples for tuberculosis diagnosis.
Samples were collected in an outside, well-ventilated space of the health centre.
Participants were offered counselling and HIV testing using OraQuick ADVANCE Rapid
HIV 1/2 Antibody Test (OraSure Technologies, Bethlehem, Pennsylvania, USA) on oral fluid.
Determine HIV 1/2 test (Abbott Laboratories, Abbott Park, IL) and Uni-Gold™ Recombigen1
HIV-1/2 (Trinity Biotech, Wicklow, Ireland) were used to confirm HIV positive results.
Linkage to TB and HIV care and vital status at 2 months
Participants diagnosed with tuberculosis were registered for treatment at the health centre.
Treatment outcomes were ascertained by extracting data from tuberculosis treatment registers.
HIV positive participants were referred to an HIV care clinic based within the health centre
for assessment for antiretroviral therapy (ART) initiation.
A follow-up study visit was organised for all participants at 2 months to assess vital status
and linkage to tuberculosis and HIV care. Participants who were unable to come to the clinic
were followed-up with a phone call or a home visit by study field workers.
Case definitions for tuberculosis
A bacteriologically confirmed tuberculosis case was defined as being a participant with a posi-
tive result by smear microscopy, Xpert1MTB/RIF or culture [15]. Participants started on
tuberculosis treatment without bacteriological confirmation were classified as having ‘clinically
diagnosed tuberculosis’.
Laboratory methods
Sputum testing for tuberculosis used LAMP as an index test, and culture as the reference stan-
dard. Sputum samples were additionally examined by fluorescence smear microscopy and
Xpert1MTB/RIF (Fig 1).
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LAMP assay procedure
LAMP was performed by a trained technician in Ndirande Health Centre’s microscopy labora-
tory. The technician had passed a proficiency test after one week training. Two spot sputum
samples were run on LAMP for each participant (Fig 1).
A semi-automated LAMP (Eiken Chemical Co., Ltd.) assay, described previously [4, 16],
was used. This LAMP assay joins manual sputum processing and DNA extraction with isother-
mal amplification and visual readout of results in a fluorescence detector. Assays were run
according to manufacturer’s instructions and results were recorded qualitatively; a positive
result when there was ‘green fluorescent light emitted’ and a negative result when there was ‘no
fluorescent light emitted’ [17].
Xpert1MTB/RIF, smear microscopy and culture
After the LAMP assay, the two spot sputum samples from each participant were transferred to
a specialist laboratory (College of Medicine, Blantyre) for concentrated smear microscopy and
culture (1st sample) and Xpert1MTB/RIF (2nd sample). Where sample volume was subopti-
mal, preference was given to the predetermined reference standard (culture).
Smear microscopy used auramine with Primo Star iLED™ (Carl Zeiss Microimaging, Ober-
kochen, Germany). Culture used BD BACTEC™MGIT™ 960 (MGIT) and Lowenstein Jensen
(LJ). Smear and culture results were interpreted by different technicians, both without refer-
ence to LAMP results.
Species identification used MPT 64 antigen test (MGIT TBc Identification test, Becton
Dickinson) plus microscopic cording; if either rapid identification test was negative then iden-
tification was based on compatible growth characteristics at various temperatures (37°C, room
temperature and 45°C) and growth on p-nitrobenzoate LJ slopes.
Fig 1. Laboratory workflow. Abbreviations: LAMP = Loop-mediated Isothermal Amplification assay; FM = fluorescence
microscopy; MGIT = Mycobacteria Growth Indicator Tube; LJ = Lowenstein Jensen media; NALC-NaOH = n-acetyl-L-cysteine
(NALC)—sodium hydroxide (NaOH). a Preference was given to investigations for ‘sputum 1’ in case of inadequate volume or
salivary specimen of one or more samples, since culture results were the predefined reference standard.
doi:10.1371/journal.pone.0155101.g001
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Statistical methods
The primary outcome was the sensitivity and specificity of LAMP compared to culture. We cal-
culated that 237 samples were required assuming a prevalence of culture confirmed tuberculo-
sis of 30% [18] and a sensitivity of LAMP on culture positive specimens of 88.2% [16],
accepting a 95% confidence interval (CI) of ± 3.75% width [19]. We conducted an exploratory
analysis of sensitivity and specificity of LAMP by HIV and smear status.
The following were other pre-planned analyses: 1) Sensitivity and specificity of each of
Xpert1MTB/RIF and fluorescence smear microscopy (with culture as reference standard); 2)
Yield of undiagnosed HIV; 3) Linkage to HIV and tuberculosis care; and 4) Vital status at 2
months.
Results of each of LAMP, Xpert MTB/RIF and fluorescence smear microscopy were coded
as “positive” or “negative”. In the exploratory comparison of the sensitivity of LAMP by smear
and HIV status, we used Fisher’s exact test. For comparing sensitivities of Xpert MTB/RIF and
fluorescence smear microscopy with LAMP, we considered this as a paired study design and
used McNemar’s test. Data analysis used Stata 13.1 (StataCorp LP, College Station, Texas) and
R version 3.2.3 (package “DTComPair”).
Cost analysis
Cost per test for each of LAMP, fluorescence smear microscopy and Xpert1MTB/RIF was
determined. For each of the diagnostic tests, complete cost data were measured considering the
following; assay costs, labour, overhead costs, building costs, maintenance costs, running costs
of building, management and supervision costs and costs associated with equipment consum-
ables and chemicals [20]. A range of batch size scenarios were observed and resource usage
during each of the test runs was recorded. The cost per test was expressed in United States dol-
lars (US$); prices available in the local currency (Malawian Kwacha) were converted into US$
based on the average United Nations operational exchange rate in 2014 [21].
Results
Recruitment
A total of 773 adults ( 15 years) were screened for cough. There were 339 adults who met the
eligibility criterion of chronic cough, of whom 273 were recruited. Reasons for exclusion are
summarised in Fig 2. Baseline characteristics, tuberculosis and HIV diagnostic outcomes are
presented in Table 1. Overall, 52% of the participants were female. Participants were mostly
young adults with a median age of 32 years (interquartile range [IQR], 25 to 41).
Yield of tuberculosis
A total of 56/273 (20.5%) participants were diagnosed with tuberculosis, 53/273 (19.4%) had
bacteriologically-confirmed tuberculosis and 3/273 (1.1%) had clinically-diagnosed tuberculo-
sis. Tuberculosis cases are shown by HIV test and method of diagnosis (i.e. smear, culture, and
Xpert1MTB/RIF) in Table 1 and Fig 2.
Yield of previously undiagnosed HIV
Overall, 92% (251/273) of participants accepted HIV testing. The prevalence of HIV was 48.2%
(121/251). Of those HIV positive, 43.8% (53/121) were newly diagnosed and 28% (34/121)
were known to be HIV positive but not yet on ART (Table 1).
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Fig 2. Recruitment of participants and distribution of TB diagnosis results. Abbreviations: MOTT =Mycobacteria other than tuberculosis;
Xpert = Xpert MTB/RIF. a Participants could not give sputum despite having cough 2 weeks. b All contaminated samples were smear negative. c
indeterminate result if culture negative and smear positive. d Missing results: 1 fluorescence smear result and 3 Xpert MTB/Rif result. e participants
with culture- and smear- negative results had ‘MTB detected low’ results on Xpert1MTB/RIF.
doi:10.1371/journal.pone.0155101.g002
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Sensitivity and specificity of LAMP
There were 233/273 (85.3%) participants who were included in the evaluation of LAMP (Fig
2). Reasons for exclusion were missing or insufficient specimen; contaminated culture results;
Table 1. Baseline characteristics and tuberculosis and HIV diagnostic outcomes.
Characteristic HIV-positive HIV-negative P-value
N (%) N (%)
Number a 121 130
Sex, female 64 (52.9) 56 (43.1) 0.120
Age (years), median (IQR) 35 (30–43) 30 (22–41) <0.001
15–24 years 10 (8.3) 40 (31.7) <0.001
25–34 years 41 (33.9) 43 (33.6)
35–44 years 45 (37.2) 20 (15.6)
45 years 25 (20.7) 25 (19.2)
Body mass index, median (IQR) 20 (18–22) 22 (19–24) 0.003
Access to HIV testing and ART
HIV positive on ART 34 (28.0)
HIV positive not on ART 34 (28.0)
New HIV positive 53 (44.0)
Conﬁrmatory HIV testing b 63/87 (72.4)
CD 4 count results b
No CD4 count result 34/87 (30.1)
0–199 29/87 (33.3)
200–349 18/87 (20.7)
350–400 4/87 (4.6)
500 2/87 (2.3)
CD 4 count (cells/mm3) median (IQR) b 175 (102–274)
Vital status at 2 months
Dead 5 (4.3) 2 (1.5) 0.298
Alive 105 (89.7) 111 (85.4)
Lost to follow-up 11 (9.1) 17 (13.1)
All TB cases c 24 (19.8) 24 (18.5) 0.782
Smear + /culture + TB 12 (9.9) 17 (13.1) 0.434
Smear—/culture + TB 4 (3.3) 2 (1.4) 0.360
Xpert1 MTB/RIF + only 6 (5.0) 4 (3.1) 0.446
Clinically diagnosed TB d 2 (1.7) 1 (0.8) 0.520
TB treated 19 (15.7) 21 (16.2) 1.000
TB treatment outcome
Cured/Completed 15/19 (78.9) 15/21 (71.4) 0.271
Dead 3/19 (15.7) 1/21 (4.8)
Lost to follow-up 1/19 (5.3) 3/21 (14.3)
Transferred out 0/19 (0.0) 2/21 (9.5)
Abbreviations: ART = antiretroviral therapy; TB = tuberculosis; + = positive;— = negative
a Participants who refused HIV test and are not shown, 22 (8.1%)
b Participants with newly diagnosed HIV or were not previously on ART were referred for conﬁrmatory HIV testing (blood testing with Determine and
UniGold) and assessment of CD 4 cell count in routine care
c 8 tuberculosis cases were diagnosed among participants with unknown HIV status, 5 of these were started on treatment, none died
d Participants who were culture negative and smear negative and were started on TB treatment based on clinical decision
doi:10.1371/journal.pone.0155101.t001
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smear-positive culture-negative results; or culture positive results due toMycobacterium other
than tuberculosis (MOTT) (Fig 1). Agreement between LAMP results on first and second sam-
ples was almost perfect (kappa = 0.94) (Fig 1). For those included in LAMP evaluation, MGIT
culture results were available for all, 233. No participant had an LJ-positive MGIT-negative
specimen. Therefore, the reference standard was entirely derived from the MGIT results.
The overall sensitivity of LAMP compared to culture was 65.0% (95% CI: 48.3% to 79.4%)
and the specificity was 100% (95% CI: 98.0% to 100%) (Table 2). Sensitivity and specificity of
LAMP did not differ significantly by HIV or smear status although power was limited for this
sub-analysis (Table 2). The sensitivity of LAMP was 66.7% (95% CI: 38.4% to 88.2%) among
HIV positive participants compared to 52.6% (95% CI: 28.9% to 75.6%) among HIV negative
participants, p = 1.000. The sensitivity of LAMP on smear-positive culture-positive specimens
was 65.7% (95% CI: 47.8% to 80.9%) compared to 60.0% (95% CI: 14.7% to 94.7%) on smear-
negative culture-positive specimens, p = 0.495.
Sensitivity and specificity of Xpert1MTB/RIF and smear microscopy
The sensitivity of concentrated fluorescence smear microscopy (87.5%, 95% CI: 73.2% to
95.8%) was higher than that of LAMP (65.0%, 95% CI: 48.3% to 79.4%), p = 0.020. The sensi-
tivity of Xpert1MTB/RIF (77.5%, 95% CI: 61.5% to 89.2%) was similar to that of LAMP,
p = 0.132. All three tests had high specificity: Xpert1MTB/RIF, 95.3% (95% CI: 91.2% to
97.8%); concentrated fluorescence smear microscopy, 100% (95% CI: 98.1% to 100%); and
LAMP, 100% (95% CI: 98.0% to 100%) (Table 3 and S2 Table).
Cost per test of LAMP, Xpert1MTB/RIF and smear microscopy
The cost per test of Xpert1MTB/RIF was more favourable than LAMP for batch sizes less
than four (Table 3). A batch of 14 samples was less costly on LAMP (US$ 9.98) than on
Xpert1MTB/RIF (US$ 13.38). Fluorescence microscopy had the lowest cost per test at all
batch sizes; the cost per test at a batch of size of 14 samples was US$ 0.65.
Linkage to HIV/tuberculosis care and vital status at 2 months
Of the 56/273 (20.5%) participants diagnosed with tuberculosis, 45/56 (80.4%) were started on
treatment by 2 months (Table 1). Pre-treatment loss to follow-up was 19.6% (11/56) reasons
were 1 withdrew from the study and 10 could not be traced by both phone call and home visit.
Table 2. Sensitivity and specificity of LAMP (compared to MGIT) by HIV status and smear status (n = 233).
Sensitivity Speciﬁcity
Overall Smear positive and culture positive Smear negative and culture positive
Overall (n = 233) a
Correct-no/total no 26/40 (65.0%) 23/35 (65.7%) 3/5 (60.0%) 193/193 (100%)
95% CI (48.3%– 79.4%) (47.8%– 80.9%) (14.7%– 94.7%) (98.0%– 100%)
HIV Positive (n = 102)
Correct-no/total no 10/15 (66.7%) 8/12 (66.7%) 2/3 (66.7%) 87/87 (100%)
95% CI (38.4%– 88.2%) (34.9%– 90.0%) (9.4%– 99.2%) (95.9%– 100%)
HIV Negative (n = 112)
Correct-no/total no 10/19 (52.6%) 9/17 (52.9%) 1/2 (50.0%) 93/93 (100%)
95% CI (28.9%– 75.6%) (27.8%– 77.0%) (1.3%– 98.7%) (96.1%– 100%)
a Includes 19 samples from participants with unknown HIV status
doi:10.1371/journal.pone.0155101.t002
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Of the 121/273 (44.3%) participants who were HIV positive, 87/121 (71.9%) participants
had newly diagnosed HIV or were known to be HIV positive but not yet on ART (Table 1).
There was a loss to participation down the continuum of HIV care; 72% (63/87) of participants
with newly diagnosed HIV or those known to be HIV positive but not yet on ART had confir-
matory HIV testing in routine care and at 2 months follow-up only 60.9% (53/87) had been
assessed for ART eligibility using CD 4 cell count (Table 1). All participants assessed had low
CD 4 cell count (175/μL,IQR, 102–274) and were eligible for ART [22].
There were 242/273 (88.6%) participants with vital status ascertained at 2 months, of whom
7/242 (2.9%) had died. Four more deaths occurred among participants treated for tuberculosis
before they completed treatment (6 months) (Table 1).
Discussion
The main finding of this study is that the sensitivity of LAMP was similar to that of Xpert1
MTB/RIF but lower than that of concentrated fluorescence smear microscopy; all three tests
Fig 3. Studies of accuracy of LAMP for diagnosis of tuberculosis. Abbreviations: TP = true positive; FP = false positive; FN = false
negative; TN = true negative. Study setting: 1 Primary care; 2 Hospital; 3 University or national reference laboratory. a Refers to findings of this
study in Malawi.b Study sites were in Peru, Bangladesh, Tanzania.
doi:10.1371/journal.pone.0155101.g003
Table 3. Diagnostic accuracy of LAMP, Xpert1MTB/RIF and fluorescence smear microscopy and cost per test at different batch sizes (n = 233).
LAMP Xpert MTB/RIF a FM microscopy
Sensitivity
Correct-no/total no 26/40 (65.0%) 31/40 (77.5%) 35/40 (87.5%)
95% CI (48.3%– 79.4%) (61.5%– 89.2%) (73.2%– 95.8%)
Speciﬁcity
Correct-no/total no 193/193 (100%) (181/190) 95.3% 192/192 (100%)
95% CI (98.1%– 100%) (91.2%– 97.8%) (98.1%– 100%)
Cost per test
2 tests per batch 16.88 14.50 -
4 tests per batch 13.38 13.01 1.42
10 tests per batch 10.65 13.51 1.23
14 tests per batch 9.98 13.38 0.65
Abbreviations: LAMP = loop-mediated isothermal ampliﬁcation assay; FM = ﬂuorescence microscopy
a 4 module Xpert1 MTB/RIF was used
doi:10.1371/journal.pone.0155101.t003
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had high specificity. Based on these data, we recommend that LAMP should not be used to
replace fluorescence smear microscopy or Xpert1MTB/RIF in peripheral laboratories of
countries like Malawi that are eligible for the “FIND-access price” for Xpert1MTB/RIF
machines and cartridges [6].
In this study, LAMP had a sensitivity of 65% and specificity of 100%. Compared to other
studies at primary care level, the sensitivity of LAMP is similar to that reported in China [17]
but lower than in Tanzania, Peru and Bangladesh [16] (Fig 3). The sensitivity of LAMP in this
study was lower than that reported from studies in hospitals [4, 23–25] and in university or
national reference laboratories [26–28] (Fig 3).
In this study, fluorescence microscopy had a high sensitivity of 87.5% and specificity of
99.5% and was the cheapest. Microscopy is highly operator-dependant and so our results are
unlikely to be generalizable to laboratories with less expertise in microscopy or less emphasis
on quality assurance. Xpert1MTB/RIF had sensitivity of 77.5% and specificity of 95.3%;
much lower than expected, sensitivity, 98.2% and specificity, 99.2% (2). Performance of
Xpert1MTB/RIF in our laboratory may have been affected by the prioritisation of smear
microscopy and culture (Fig 1).
Pre-treatment loss to follow-up among tuberculosis patients was 19.6% and falls in range of
6 to 30% reported from studies in Africa [29]. Pre-treatment loss to follow-up is due to: indi-
vidual factors like male sex, older age, being diagnosed with smear-negative but culture-posi-
tive tuberculosis; and system related factors including delays in receiving results, long waiting
times in health services, the need for repeated visits, and geographical location of the tuberculo-
sis laboratory (regional versus local) [29].
Linkage to HIV care was suboptimal, with only 60.9% of participants in need of ART suc-
cessfully assessed for ART initiation at 2 months. This suboptimal linkage to assessment for
ART has also been reported among adults identified in the community, 56.3% [30] and in a
primary care clinic 54.6% [31] and is influenced by many factors including the individual’s
social support networks, attitude of health workers and the organisation of patient flow in
health facilities [32].
There are a number of limitations to this study. LAMP was conducted at primary care level
while Xpert1MTB/RIF and fluorescence microscopy were conducted at a research laboratory
with more rigorous laboratory standards. Due to the small sample size, we were unable to
investigate sensitivity and specificity of LAMP by HIV or smear status. The sensitivity of
Xpert1MTB/RIF was affected by the prioritisation of microscopy and culture over Xpert1
MTB/RIF. Diagnosis of tuberculosis was mainly based on sputum. Participants who were not
able to submit sputum were not actively investigated for tuberculosis e.g. with chest radiogra-
phy or sputum induction.
Conclusion
The sensitivity of LAMP was similar Xpert1MTB/RIF but lower than concentrated fluores-
cence smear microscopy; all three tests had high specificity. LAMP should not replace fluores-
cence smear microscopy or Xpert1MTB/RIF. These findings support the Malawi policy that
recommends a combination of fluorescence microscopy and Xpert1MTB/RIF prioritised for
people living with HIV, already found to be smear-negative, or being considered for retreat-
ment of tuberculosis.
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